Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection Subject dosing commenced SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. – November 26, 2018 - Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The commencement of first